Evidence map›Paper›PMID 39736890›Full record

ReviewFrontiers in pediatrics2024

Variants in

Elaina Solano, Aleksandra Foksinska, Camerron M Crowder

Abstract readReview
In one paragraph

Review in Frontiers in pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Elaina SolanoDepartment of Neurobiology, University of Alabama at Birmingham, Birmingham, AL, United States.
Aleksandra FoksinskaHugh Kaul Precision Medicine Institute, University of Alabama at Birmingham, Birmingham, AL, United States.
Camerron M CrowderDepartment of Neurobiology, University of Alabama at Birmingham, Birmingham, AL, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RHOBTB2 is a member of the Rho GTPases subfamily of signaling proteins, known tumor suppressors whose loss of function and decreased expression is associated with cancer onset. Beyond its cancer-related role, RHOBTB2 is implicated in rare neurodevelopmental disorders, specifically

Indexed as

cancerdevelopmental and epileptic encephalopathygenetic variantsneurodevelopmental disorderprecision medicineRHOBTB2-related disorderstumor suppressor

Identifiers

PMID39736890
PMCPMC11683136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.